• WM-8014: What the Product Record Supports

  2026-10-14

  The APExBIO product record describes WM-8014 as a reversible, competitive inhibitor of MYST-family acetyltransferases, with highest reported biochemical potency toward KAT6A and KAT6B. It also attributes cell-cycle arrest, senescence-associated molecular changes, and reduced proliferation in a KRAS-driven zebrafish liver model to the compound. Because no identity-matched paper, methods, sample sizes, statistical estimates, or independent validation are available here, these statements should be treated as product-level claims rather than a complete evidence base.

• Methyl-β-cyclodextrin: Scope and Evidence

  2026-10-14

  Methyl-β-cyclodextrin (MβCD; APExBIO SKU C6939) is documented by the supplier as a research reagent intended to interact with membrane-associated cholesterol and other hydrophobic lipids. The available evidence is limited to product information, so its conceptual relevance to membrane cholesterol extraction, lipid raft disruption, and membrane fluidity modulation should not be treated as a peer-reviewed demonstration of biological outcomes.

• Methyl-β-cyclodextrin: Identity and Evidence Scope

  2026-10-13

  A source-limited overview of APExBIO’s Methyl-β-cyclodextrin product, its proposed membrane-research scope, and the absence of a matched primary paper.

• Methyl-β-cyclodextrin: Identity and Evidence Scope

  2026-10-13

  Methyl-β-cyclodextrin is a vendor-described methylated β-cyclodextrin reagent associated with conceptual studies of membrane cholesterol, lipid organization and membrane fluidity. The supplied evidence supports product identity and intended research scope, but no matched primary paper or independent outcome data were provided.

• SB 431542 and Evidence in Limb Organoids

  2026-10-12

  Skoufa et al. use SB 431542 within a mouse stem-cell-derived organoid framework to study ectoderm–mesoderm interactions. The findings support a role for AER-like cells in cell-state organization and tissue polarization, but the supplied evidence does not isolate ALK5 from related receptor activity or establish that SB 431542 alone explains the observed developmental effects.

• What EdU Measures in LUAD Proliferation Studies

  2026-10-12

  EdU imaging reports DNA synthesis during S phase, not proliferation in every biological sense. This overview separates the assay’s conceptual readout from the findings of a recent lung adenocarcinoma study and explains evidence limitations, supplier provenance, and applicability boundaries.

• Carbapenemase Gene Transmission in CREC

  2026-10-10

  A 2025 BMC Microbiology study integrates gene localization, antimicrobial susceptibility, mobile-element analysis, transferability testing, and strain typing across eight Guangdong teaching hospitals. Its findings show that blaNDM-1 was predominant, frequently plasmid-associated, and linked to multidrug resistance, while the evidence for dissemination potential was substantial but not equivalent to direct outbreak transmission proof.

• Angiotensin III: From RAAS Biology to Translation

  2026-10-09

  Angiotensin III is more than a downstream RAAS fragment: it is a defined molecular probe for aldosterone regulation, receptor signaling, neuroendocrine physiology, and emerging peptide–host receptor biology. This thought-leadership analysis connects established mechanisms with recent SARS-CoV-2 spike-binding findings while distinguishing biochemical evidence from translational implication.

• FTH and Ferroptosis Sensitivity in TP53-Mutant GBM

  2026-10-09

  A 2025 study links TP53 mutation in glioblastoma models to disrupted iron handling through ITCH-associated degradation of ferritin heavy chain (FTH). The findings suggest that altered iron storage may create a context-dependent vulnerability to ferroptosis, although the evidence remains primarily computational and cell-based rather than clinical.

• Angiotensin Peptides and SARS-CoV-2 Receptor Binding

  2026-10-08

  Oliveira and colleagues report that naturally occurring angiotensin peptides can alter the measured binding of SARS-CoV-2 spike protein to host receptors, with particularly strong sequence-dependent effects involving AXL and angiotensin IV. The study provides a biochemical, hypothesis-generating connection between renin–angiotensin signaling and viral receptor engagement, but it does not establish increased infection or disease risk in vivo.

• Tranexamic Acid in Instant Clot-Forming Dressings

  2026-10-08

  The reference study presents a bilayer wound dressing that combines tranexamic acid, an NO donor, and propolis to address rapid clot stabilization and bacterial contamination. Its in vitro findings support the concept of integrated hemostatic and antibacterial wound materials, while remaining preliminary for clinical bleeding control and infection prevention.

• Potassium Phosphate Monobasic in LNP Drying Research

  2026-10-07

  Potassium phosphate monobasic, or KH2PO4, is widely associated with biochemical buffer systems, but current literature does not establish it as a universal stabilizer for dried mRNA-lipid nanoparticles. This overview separates supplier information from published evidence and examines how phosphate-buffer context may enter research on drying, reconstitution, particle quality, and biological potency.

• VX-702 and p38α MAPK Research Context

  2026-10-07

  VX-702 is a supplier-described p38α MAPK inhibitor used as a research probe in inflammation, kinase signaling, platelet biology, and injury models. This overview separates established mechanistic findings from supplier-reported results and explains the limits of translating preclinical evidence to human disease.

• A-1331852 and BCL-XL Targeting in GBM

  2026-10-06

  A source-grounded overview of A-1331852 as a research probe for BCL-XL biology, with emphasis on glioblastoma, apoptotic priming, published BH3-mimetic findings, evidence strength, and limitations. The available evidence supports a rationale for studying BCL-2 family protein inhibition in selected GBM models, but it does not establish clinical efficacy or prove that all reported GBM findings are specific to A-1331852.

• XAV939, Wnt/β-Catenin, and DSS Colitis

  2026-10-05

  A 2025 study tested whether pharmacologic inhibition of Wnt/β-catenin signaling with XAV939 could reduce inflammation in a DSS-induced mouse model of ulcerative colitis. Although XAV939 suppressed pathway-associated proteins and SOX9, it did not improve intestinal morphology, inflammatory status, or DSS-associated changes in Villin and PPARγ, indicating that pathway inhibition alone may not be sufficient in this model.

3650 records 1/244 page Next 12345 下5页 Last page